NASDAQ:VCYT - Veracyte Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$7.50 -0.23 (-2.98 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$7.50
Today's Range$7.38 - $7.78
52-Week Range$5.23 - $9.80
Volume67,309 shs
Average Volume113,563 shs
Market Capitalization$260.34 million
P/E Ratio-8.24
Dividend YieldN/A
Beta1.61

About Veracyte (NASDAQ:VCYT)

Veracyte logoVeracyte, Inc. operates as a genomic diagnostics company in the United States. The company uses genomic technology to resolve diagnostic uncertainty. It offers Afirma Thyroid FNA Analysis solution; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients. The company's products also include Percepta Bronchial Genomic Classifier solution for use in lung cancer screening and diagnosis; and Envisia Genomic Classifier solution for idiopathic pulmonary fibrosis. Veracyte, Inc. sells its products through product specialists, institutional managers, account managers, and medical science specialists. Veracyte, Inc. has research collaboration agreement with Loxo Oncology to develop medicines for patients with genetically defined cancers. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Receive VCYT News and Ratings via Email

Sign-up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VCYT
CUSIPN/A
Phone650-243-6300

Debt

Debt-to-Equity Ratio0.84
Current Ratio3.98
Quick Ratio3.59

Price-To-Earnings

Trailing P/E Ratio-8.24
Forward P/E Ratio-7.50
P/E GrowthN/A

Sales & Book Value

Annual Sales$71.95 million
Price / Sales3.58
Cash FlowN/A
Price / CashN/A
Book Value$0.87 per share
Price / Book8.62

Profitability

EPS (Most Recent Fiscal Year)($0.91)
Net Income$-31,000,000.00
Net Margins-42.30%
Return on Equity-80.99%
Return on Assets-39.72%

Miscellaneous

Employees246
Outstanding Shares34,350,000

Veracyte (NASDAQ:VCYT) Frequently Asked Questions

What is Veracyte's stock symbol?

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

How were Veracyte's earnings last quarter?

Veracyte Inc (NASDAQ:VCYT) announced its earnings results on Tuesday, May, 1st. The biotechnology company reported ($0.27) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.02. The biotechnology company had revenue of $20.04 million for the quarter, compared to analyst estimates of $18.28 million. Veracyte had a negative return on equity of 80.99% and a negative net margin of 42.30%. View Veracyte's Earnings History.

What price target have analysts set for VCYT?

4 Wall Street analysts have issued 1 year price targets for Veracyte's stock. Their predictions range from $5.40 to $15.00. On average, they expect Veracyte's share price to reach $10.60 in the next twelve months. View Analyst Ratings for Veracyte.

Who are some of Veracyte's key competitors?

Who are Veracyte's key executives?

Veracyte's management team includes the folowing people:
  • Ms. Bonnie H. Anderson, Co-Founder, Chairman & CEO (Age 60)
  • Mr. Christopher M. Hall, Pres & COO (Age 49)
  • Mr. Keith S. Kennedy CFA, CPA, CFO & Principal Accounting Officer (Age 48)
  • Dr. Giulia C. Kennedy Ph.D., Chief Scientific Officer & Head of Scientific, Clinical and Medical Affairs Department (Age 59)
  • Mr. Ashish Kheterpal, Chief Information Officer

Has Veracyte been receiving favorable news coverage?

Media coverage about VCYT stock has been trending positive on Saturday, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Veracyte earned a news impact score of 0.36 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 47.59 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Veracyte's major shareholders?

Veracyte's stock is owned by many different of retail and institutional investors. Top institutional investors include Acuta Capital Partners LLC (9.66%), Cannell Capital LLC (5.99%), BlackRock Inc. (5.27%), First Light Asset Management LLC (2.47%), Millennium Management LLC (2.11%) and Algert Global LLC (0.39%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones and Jesse I Treu. View Institutional Ownership Trends for Veracyte.

Which institutional investors are selling Veracyte stock?

VCYT stock was sold by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Algert Global LLC, Millennium Management LLC, BlackRock Inc. and Quantum Capital Management. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Christopher M Hall and Evan/ Fa Jones. View Insider Buying and Selling for Veracyte.

Which institutional investors are buying Veracyte stock?

VCYT stock was bought by a variety of institutional investors in the last quarter, including Cannell Capital LLC, JPMorgan Chase & Co., First Light Asset Management LLC and Acuta Capital Partners LLC. View Insider Buying and Selling for Veracyte.

How do I buy shares of Veracyte?

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Veracyte's stock price today?

One share of VCYT stock can currently be purchased for approximately $7.50.

How big of a company is Veracyte?

Veracyte has a market capitalization of $260.34 million and generates $71.95 million in revenue each year. The biotechnology company earns $-31,000,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Veracyte employs 246 workers across the globe.

How can I contact Veracyte?

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]


MarketBeat Community Rating for Veracyte (VCYT)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  234 (Vote Outperform)
Underperform Votes:  137 (Vote Underperform)
Total Votes:  371
MarketBeat's community ratings are surveys of what our community members think about Veracyte and other stocks. Vote "Outperform" if you believe VCYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCYT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Veracyte (NASDAQ:VCYT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Veracyte in the last 12 months. Their average twelve-month price target is $10.60, suggesting that the stock has a possible upside of 41.33%. The high price target for VCYT is $15.00 and the low price target for VCYT is $5.40. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.602.602.60
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $10.60$11.08$12.50$12.50
Price Target Upside: 41.33% upside93.03% upside95.31% upside95.31% upside

Veracyte (NASDAQ:VCYT) Consensus Price Target History

Price Target History for Veracyte (NASDAQ:VCYT)

Veracyte (NASDAQ:VCYT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/2/2018BTIG ResearchSet Price TargetBuy$13.00LowView Rating Details
3/1/2018Piper Jaffray CompaniesReiterated RatingHold$5.40LowView Rating Details
11/7/2017Leerink SwannLower Price TargetOutperform$12.00 ➝ $9.00N/AView Rating Details
11/7/2017Janney Montgomery ScottDowngradeBuy ➝ NeutralN/AView Rating Details
5/18/2017Cantor FitzgeraldSet Price TargetBuy$13.00LowView Rating Details
10/18/2016William BlairReiterated RatingOutperformN/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Veracyte (NASDAQ:VCYT) Earnings History and Estimates Chart

Earnings by Quarter for Veracyte (NASDAQ:VCYT)

Veracyte (NASDAQ:VCYT) Earnings Estimates

2018 EPS Consensus Estimate: ($0.97)
2019 EPS Consensus Estimate: ($0.67)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.26)($0.25)($0.26)
Q2 20183($0.30)($0.21)($0.26)
Q3 20183($0.29)($0.20)($0.24)
Q4 20183($0.25)($0.17)($0.21)
Q1 20193($0.25)($0.20)($0.22)
Q2 20193($0.20)($0.14)($0.17)
Q3 20193($0.19)($0.14)($0.16)
Q4 20193($0.18)($0.08)($0.12)

Veracyte (NASDAQ VCYT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018Q1 2018($0.25)($0.27)$18.28 million$20.04 millionViewListenView Earnings Details
2/27/2018Q4 2017($0.21)($0.24)$18.84 million$19.60 millionViewN/AView Earnings Details
11/6/2017Q3 2017($0.21)($0.21)$19.54 million$17.50 millionViewN/AView Earnings Details
7/31/2017Q2 2017($0.25)($0.22)$18.32 million$18.40 millionViewN/AView Earnings Details
5/3/2017Q1 2017($0.24)($0.24)$18.09 million$16.43 millionViewListenView Earnings Details
3/1/2017Q416($0.26)($0.14)$17.49 million$18.30 millionViewListenView Earnings Details
11/3/2016Q316($0.36)($0.20)$15.76 million$18.60 millionViewN/AView Earnings Details
8/3/2016Q216($0.33)($0.40)$14.80 million$14.68 millionViewN/AView Earnings Details
5/5/2016Q116($0.35)($0.36)$13.08 million$13.55 millionViewN/AView Earnings Details
3/10/2016Q415($0.30)($0.29)$14.45 million$14.04 millionViewListenView Earnings Details
11/5/2015Q315($0.33)($0.32)$12.72 million$12.33 millionViewListenView Earnings Details
8/13/2015Q215($0.31)($0.35)$12.23 million$11.90 millionViewListenView Earnings Details
5/14/2015Q115($0.37)($0.34)$10.83 million$11.20 millionViewListenView Earnings Details
3/19/2015Q414($0.33)($0.36)$11.83 million$12.20 millionViewN/AView Earnings Details
11/13/2014Q314($0.35)($0.37)$9.67 million$9.80 millionViewN/AView Earnings Details
8/13/2014Q214($0.33)($0.31)$9.36 million$8.70 millionViewN/AView Earnings Details
5/8/2014Q114($0.31)($0.32)$7.19 million$7.50 millionViewN/AView Earnings Details
3/18/2014Q4($0.38)($0.42)$6.43 million$6.84 millionViewListenView Earnings Details
11/25/2013Q313($6.59)$3.20 million$5.60 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Veracyte (NASDAQ:VCYT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Veracyte (NASDAQ VCYT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 71.51%
Insider Trading History for Veracyte (NASDAQ:VCYT)
Institutional Ownership by Quarter for Veracyte (NASDAQ:VCYT)

Veracyte (NASDAQ VCYT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/20/2017Bonnie H AndersonChairmanSell16,000$9.41$150,560.0016,000View SEC Filing  
10/18/2017Bonnie H AndersonCEOSell6,000$9.09$54,540.0016,000View SEC Filing  
10/2/2017Christopher M HallInsiderSell20,000$9.00$180,000.00View SEC Filing  
9/25/2017Bonnie H AndersonChairmanSell6,000$8.44$50,640.0016,000View SEC Filing  
8/28/2017Evan/ Fa JonesDirectorSell22,500$7.81$175,725.00View SEC Filing  
8/24/2017Evan/ Fa JonesDirectorSell40,000$7.88$315,200.00View SEC Filing  
8/23/2017Evan/ Fa JonesDirectorSell20,000$7.92$158,400.00View SEC Filing  
5/16/2017Jesse I TreuDirectorSell2,226$8.08$17,986.081,642View SEC Filing  
3/21/2017Bonnie H AndersonChairmanSell5,000$9.09$45,450.0015,000View SEC Filing  
6/3/2016Bonnie H AndersonCEOBuy5,000$5.40$27,000.007,500View SEC Filing  
6/1/2016Bonnie H AndersonCEOBuy5,000$5.46$27,300.002,500View SEC Filing  
5/31/2016Bonnie H AndersonCEOBuy2,500$5.46$13,650.002,500View SEC Filing  
11/25/2015Evan/ Fa JonesDirectorSell7,896$7.23$57,088.08View SEC Filing  
11/24/2015Evan/ Fa JonesDirectorSell7,104$7.20$51,148.80View SEC Filing  
7/22/2015Christopher M HallCOOSell2,500$11.85$29,625.00View SEC Filing  
6/26/2015Shelly D GuyerCFOSell1,000$12.08$12,080.00View SEC Filing  
9/10/2014Christopher M HallInsiderSell1,000$12.29$12,290.00View SEC Filing  
9/9/2014Evan/ Fa JonesDirectorSell27,304$12.60$344,030.40View SEC Filing  
8/18/2014Christopher M HallInsiderSell1,000$12.92$12,920.00View SEC Filing  
7/29/2014Julie BrooksEVPBuy1,122$14.69$16,482.18View SEC Filing  
7/28/2014Julie BrooksEVPBuy1,000$14.71$14,710.00View SEC Filing  
7/22/2014Julie BrooksVPBuy2,000$14.18$28,360.00View SEC Filing  
7/21/2014Julie BrooksVPBuy1,000$14.00$14,000.00View SEC Filing  
7/10/2014Christopher M HallInsiderSell3,000$14.92$44,760.00View SEC Filing  
6/27/2014Bonnie H AndersonCEOSell1,000$17.95$17,950.00View SEC Filing  
6/23/2014Bonnie H AndersonCEOSell4,000$16.45$65,800.00View SEC Filing  
6/23/2014Christopher M HallInsiderSell2,000$16.95$33,900.00View SEC Filing  
6/20/2014Shelly D GuyerCFOSell1,250$16.04$20,050.00View SEC Filing  
6/19/2014Christopher M HallInsiderSell3,000$14.99$44,970.00View SEC Filing  
6/12/2014Evan/ Fa JonesDirectorSell16,650$15.07$250,915.50View SEC Filing  
6/9/2014Evan/ Fa JonesDirectorSell22,870$14.57$333,215.90View SEC Filing  
6/5/2014Evan/ Fa JonesDirectorSell28,248$14.33$404,793.84View SEC Filing  
5/30/2014Evan/ Fa JonesDirectorSell23,882$15.33$366,111.06View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Veracyte (NASDAQ VCYT) News Headlines

Source:
DateHeadline
Veracyte Inc (VCYT) Expected to Announce Earnings of -$0.27 Per ShareVeracyte Inc (VCYT) Expected to Announce Earnings of -$0.27 Per Share
www.americanbankingnews.com - May 25 at 5:15 AM
Veracyte Announces New Study Published in JAMA Surgery Demonstrates Afirma GSC’s Ability to Significantly Reduce Unnecessary Surgeries in Thyroid Cancer DiagnosisVeracyte Announces New Study Published in JAMA Surgery Demonstrates Afirma GSC’s Ability to Significantly Reduce Unnecessary Surgeries in Thyroid Cancer Diagnosis
finance.yahoo.com - May 23 at 4:36 PM
Veracyte : Data From Multiple Studies Show Value Of Afirma Genomic SequencingVeracyte : Data From Multiple Studies Show Value Of Afirma Genomic Sequencing
www.nasdaq.com - May 19 at 4:36 PM
Veracyte Launches Early Access Program for Envisia Genomic Classifier to Improve Diagnosis of IPFVeracyte Launches Early Access Program for Envisia Genomic Classifier to Improve Diagnosis of IPF
finance.yahoo.com - May 17 at 9:43 AM
Veracyte Announces Launch of New Afirma Xpression Atlas at 2018 AACE CongressVeracyte Announces Launch of New Afirma Xpression Atlas at 2018 AACE Congress
finance.yahoo.com - May 16 at 4:31 PM
Veracyte to Launch New Afirma Xpression Atlas and Present Platform Performance Data at AACE 2018 MeetingVeracyte to Launch New Afirma Xpression Atlas and Present Platform Performance Data at AACE 2018 Meeting
finance.yahoo.com - May 10 at 9:40 AM
**UPDATED WITH NEW TIME**: Veracyte to Present at the 2018 UBS Global Healthcare Conference**UPDATED WITH NEW TIME**: Veracyte to Present at the 2018 UBS Global Healthcare Conference
finance.yahoo.com - May 10 at 9:40 AM
Veracyte to Present at the 2018 UBS Global Healthcare ConferenceVeracyte to Present at the 2018 UBS Global Healthcare Conference
finance.yahoo.com - May 9 at 9:29 AM
Veracyte (VCYT) Expected to Post Quarterly Sales of $20.58 MillionVeracyte (VCYT) Expected to Post Quarterly Sales of $20.58 Million
www.americanbankingnews.com - May 9 at 1:44 AM
-$0.26 EPS Expected for Veracyte (VCYT) This Quarter-$0.26 EPS Expected for Veracyte (VCYT) This Quarter
www.americanbankingnews.com - May 7 at 9:12 PM
Veracyte (VCYT) Receives Average Recommendation of "Hold" from BrokeragesVeracyte (VCYT) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 7 at 10:33 AM
Comparing Elekta (EKTAY) and Veracyte (VCYT)Comparing Elekta (EKTAY) and Veracyte (VCYT)
www.americanbankingnews.com - May 7 at 10:33 AM
Leerink Swann Comments on Veracytes Q2 2018 Earnings (VCYT)Leerink Swann Comments on Veracyte's Q2 2018 Earnings (VCYT)
www.americanbankingnews.com - May 7 at 1:18 AM
Veracyte (VCYT) Expected to Earn Q2 2018 Earnings of ($0.26) Per ShareVeracyte (VCYT) Expected to Earn Q2 2018 Earnings of ($0.26) Per Share
www.americanbankingnews.com - May 4 at 5:56 AM
Reviewing Veracyte (VCYT) & Its RivalsReviewing Veracyte (VCYT) & Its Rivals
www.americanbankingnews.com - May 3 at 3:00 PM
Veracyte (VCYT) Given a $13.00 Price Target by BTIG Research AnalystsVeracyte (VCYT) Given a $13.00 Price Target by BTIG Research Analysts
www.americanbankingnews.com - May 3 at 12:52 PM
Comparing Veracyte (VCYT) & Its PeersComparing Veracyte (VCYT) & Its Peers
www.americanbankingnews.com - May 3 at 5:34 AM
Head to Head Contrast: Veracyte (VCYT) & Its PeersHead to Head Contrast: Veracyte (VCYT) & Its Peers
www.americanbankingnews.com - May 2 at 5:38 PM
Veracyte (VCYT) Announces Quarterly  Earnings ResultsVeracyte (VCYT) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 2 at 1:40 PM
Veracyte misses by $0.02, beats on revenueVeracyte misses by $0.02, beats on revenue
seekingalpha.com - May 2 at 9:24 AM
Edited Transcript of VCYT earnings conference call or presentation 1-May-18 8:30pm GMTEdited Transcript of VCYT earnings conference call or presentation 1-May-18 8:30pm GMT
finance.yahoo.com - May 2 at 9:24 AM
Veracyte: 1Q Earnings SnapshotVeracyte: 1Q Earnings Snapshot
finance.yahoo.com - May 2 at 9:24 AM
Veracyte (VCYT) versus The Competition Head-To-Head ComparisonVeracyte (VCYT) versus The Competition Head-To-Head Comparison
www.americanbankingnews.com - May 2 at 5:14 AM
Veracyte (VCYT) versus Its Peers Head to Head ContrastVeracyte (VCYT) versus Its Peers Head to Head Contrast
www.americanbankingnews.com - May 2 at 1:08 AM
Analyzing Veracyte (VCYT) and Its CompetitorsAnalyzing Veracyte (VCYT) and Its Competitors
www.americanbankingnews.com - April 26 at 9:38 AM
Veracyte (VCYT) Set to Announce Quarterly Earnings on TuesdayVeracyte (VCYT) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 24 at 10:56 AM
Reviewing Veracyte (VCYT) & The CompetitionReviewing Veracyte (VCYT) & The Competition
www.americanbankingnews.com - April 22 at 7:28 AM
$18.28 Million in Sales Expected for Veracyte (VCYT) This Quarter$18.28 Million in Sales Expected for Veracyte (VCYT) This Quarter
www.americanbankingnews.com - April 22 at 1:58 AM
Veracyte (VCYT) Expected to Post Earnings of -$0.25 Per ShareVeracyte (VCYT) Expected to Post Earnings of -$0.25 Per Share
www.americanbankingnews.com - April 20 at 7:14 PM
Q3 2018 EPS Estimates for Veracyte Increased by Piper Jaffray (VCYT)Q3 2018 EPS Estimates for Veracyte Increased by Piper Jaffray (VCYT)
www.americanbankingnews.com - April 20 at 8:02 AM
Veracyte (VCYT) vs. Its Rivals Critical AnalysisVeracyte (VCYT) vs. Its Rivals Critical Analysis
www.americanbankingnews.com - April 18 at 11:14 AM
Contrasting Veracyte (VCYT) & Its CompetitorsContrasting Veracyte (VCYT) & Its Competitors
www.americanbankingnews.com - April 17 at 5:20 PM
Veracyte to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results on Tuesday, May 1, 2018Veracyte to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results on Tuesday, May 1, 2018
finance.yahoo.com - April 17 at 4:53 PM
Veracyte (VCYT) Rating Lowered to Strong Sell at BidaskClubVeracyte (VCYT) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - April 17 at 12:21 PM
Comparing Veracyte (VCYT) and The CompetitionComparing Veracyte (VCYT) and The Competition
www.americanbankingnews.com - April 15 at 9:09 PM
Head to Head Comparison: Veracyte (VCYT) vs. Its RivalsHead to Head Comparison: Veracyte (VCYT) vs. Its Rivals
www.americanbankingnews.com - April 13 at 9:31 AM
Veracyte (VCYT) Given a $13.00 Price Target at BTIG ResearchVeracyte (VCYT) Given a $13.00 Price Target at BTIG Research
www.americanbankingnews.com - April 12 at 10:19 AM
Veracyte (VCYT) Receives Consensus Rating of "Hold" from BrokeragesVeracyte (VCYT) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - April 12 at 9:51 AM
Critical Review: Veracyte (VCYT) & Its RivalsCritical Review: Veracyte (VCYT) & Its Rivals
www.americanbankingnews.com - April 12 at 9:11 AM
Head to Head Comparison: Veracyte (VCYT) & Its CompetitorsHead to Head Comparison: Veracyte (VCYT) & Its Competitors
www.americanbankingnews.com - April 12 at 1:15 AM
Veracyte (VCYT) & Its Peers Head-To-Head AnalysisVeracyte (VCYT) & Its Peers Head-To-Head Analysis
www.americanbankingnews.com - April 9 at 7:21 PM
Head-To-Head Analysis: Veracyte (VCYT) versus Its PeersHead-To-Head Analysis: Veracyte (VCYT) versus Its Peers
www.americanbankingnews.com - April 8 at 7:20 AM
Zacks: Analysts Anticipate Veracyte (VCYT) Will Announce Quarterly Sales of $18.32 MillionZacks: Analysts Anticipate Veracyte (VCYT) Will Announce Quarterly Sales of $18.32 Million
www.americanbankingnews.com - April 5 at 2:12 AM
Biocept (BIOC) vs. Veracyte (VCYT) Head to Head ContrastBiocept (BIOC) vs. Veracyte (VCYT) Head to Head Contrast
www.americanbankingnews.com - April 4 at 9:20 PM
Veracyte (VCYT) versus The Competition Financial ComparisonVeracyte (VCYT) versus The Competition Financial Comparison
www.americanbankingnews.com - April 4 at 3:06 AM
Zacks: Brokerages Anticipate Veracyte (VCYT) to Post -$0.25 EPSZacks: Brokerages Anticipate Veracyte (VCYT) to Post -$0.25 EPS
www.americanbankingnews.com - April 3 at 9:19 PM
Veracyte (VCYT) Downgraded to Neutral at Piper JaffrayVeracyte (VCYT) Downgraded to Neutral at Piper Jaffray
www.americanbankingnews.com - April 1 at 4:48 PM
Veracyte Inc (VCYT) to Post Q1 2019 Earnings of ($0.21) Per Share, William Blair ForecastsVeracyte Inc (VCYT) to Post Q1 2019 Earnings of ($0.21) Per Share, William Blair Forecasts
www.americanbankingnews.com - March 23 at 12:34 PM
Veracyte Unveils Afirma Xpression Atlas Platform at ENDO 2018Veracyte Unveils Afirma Xpression Atlas Platform at ENDO 2018
finance.yahoo.com - March 19 at 4:22 PM
Veracyte Announces New Data Suggesting Afirma GSC’s Ability to Help Significantly More Patients Avoid Unnecessary Thyroid SurgeryVeracyte Announces New Data Suggesting Afirma GSC’s Ability to Help Significantly More Patients Avoid Unnecessary Thyroid Surgery
finance.yahoo.com - March 19 at 9:39 AM

SEC Filings

Veracyte (NASDAQ:VCYT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Veracyte (NASDAQ:VCYT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Veracyte (NASDAQ VCYT) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.